Baseline Plasma GPX3 Level Predicts Efficacy of Insulin-Sensitization Drug Chiglitazar in Type 2 Diabetes.

ABSTRACT:

SUBMITTER: Cao Z 

PROVIDER: S-EPMC12391574 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature